генерици

On 05.07.2018, EMA – the European Medicines Agency, issued a statement on the so-called “precautionary recall” of valsartan-containing products due to a received signal for a detected adulteration in the raw substance, namely NDMA – N-nitrosodimethylamine. The signal was submitted by the manufacturing company, namely the China-based “Zhejiang Huahai …

|Full text of the analysis| Summary and conclusions from the analysis of the sartan group: The results of this study confirm the conclusions of previous analyses, such as the World Bank's 2015 analysis, as well as good practices from EU countries, and quantify the positive effects of implementing a progeneric policy within the framework of …

After the latest upheavals in the healthcare sector, it is necessary for the power to be taken over by an expert who can offer optimal solutions to the problems in the sector - ones that will not harm the budget and will optimize the consumption of money from health contributions to the extent that they meet ...